Literature DB >> 14737111

The MAP kinase pathway is required for entry into mitosis and cell survival.

Xiaoqi Liu1, Shi Yan, Tianhua Zhou, Yasuhiko Terada, Raymond L Erikson.   

Abstract

In this communication, we examined the role of the MAP kinase pathway in the G2/M phase of the cell cycle. Activation of the Plk1 and MAP kinase pathways was initially evaluated in FT210 cells, which arrest at G2 phase at the restrictive temperature (39 degrees C), due to a mutation in the cdc2 gene. Previous studies had shown that these cells enter mitosis at the nonpermissive temperature upon incubation with okadaic acid, a protein phosphatase 1 and 2A inhibitor. We show that treatment of FT210 cells at 39 degrees C with okadaic acid activated Plk1, as shown by hyperphosphorylation and elevated protein kinase activity, and also induced activation of the MAP kinase pathway. The specific Mek inhibitor PD98059 antagonized the okadaic acid-induced activation of both Plk1 and MAP kinases. This suggests that activation of the MAP kinase pathway may contribute to the okadaic acid-induced activation of Plk1 in FT210 cells at 39 degrees C. We also found that PD98059 strongly attenuated progression of HeLa cells through mitosis, and active Mek colocalizes with Plk1 at mitotic structures. To study the potential function of the MAP kinase pathway during mitosis, RNAi was used to specifically deplete five members of this pathway (Raf1, Mek1/2, Erk1/2). Each of these five protein kinases is required for cell proliferation and survival, and depletion of any of these proteins eventually leads to apoptosis. Treatment with Mek inhibitors also inhibited cell proliferation and caused apoptosis. A dramatic increase of Plk1 activities and a moderate increase of Cdc2 activities in Raf1-depleted cells indicate that Raf1-depleted cells arrest in the late G2 or M phase. Mek1 and Erk1 depletion also caused cell cycle arrest at G2, suggesting that these enzymes are required for the G2/M transition, whereas the loss of Mek2 or Erk2 caused arrest at G1.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14737111     DOI: 10.1038/sj.onc.1207188

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  55 in total

1.  Transcriptional repression of Mad-Max complex by human umbilical cord blood stem cells downregulates extracellular signal-regulated kinase in glioblastoma.

Authors:  Kiran Kumar Velpula; Venkata Ramesh Dasari; Andrew J Tsung; Dzung H Dinh; Jasti S Rao
Journal:  Stem Cells Dev       Date:  2011-11-21       Impact factor: 3.272

2.  A mammalian NudC-like protein essential for dynein stability and cell viability.

Authors:  Tianhua Zhou; Wendy Zimmerman; Xiaoqi Liu; Raymond L Erikson
Journal:  Proc Natl Acad Sci U S A       Date:  2006-06-05       Impact factor: 11.205

3.  Deletion of ERK2 mitogen-activated protein kinase identifies its key roles in cortical neurogenesis and cognitive function.

Authors:  Ivy S Samuels; J Colleen Karlo; Alicia N Faruzzi; Kathryn Pickering; Karl Herrup; J David Sweatt; Sulagna C Saitta; Gary E Landreth
Journal:  J Neurosci       Date:  2008-07-02       Impact factor: 6.167

4.  Activation of extracellular signal-regulated kinase (ERK) in G2 phase delays mitotic entry through p21CIP1.

Authors:  S Dangi; F M Chen; P Shapiro
Journal:  Cell Prolif       Date:  2006-08       Impact factor: 6.831

5.  Ulva pertusa lectin 1 delivery through adenovirus vector affects multiple signaling pathways in cancer cells.

Authors:  Gongchu Li; Zhenzhen Zhao; Bingbing Wu; Qunshu Su; Liqin Wu; Xinyan Yang; Jing Chen
Journal:  Glycoconj J       Date:  2017-03-27       Impact factor: 2.916

6.  The activity of extracellular signal-regulated kinase is required during G2/M phase before metaphase-anaphase transition in synchronized leukemia cell lines.

Authors:  Katarina Matkovic; Vesna Lukinovic-Skudar; Hrvoje Banfic; Dora Visnjic
Journal:  Int J Hematol       Date:  2009-01-17       Impact factor: 2.490

7.  Bora and the kinase Aurora a cooperatively activate the kinase Plk1 and control mitotic entry.

Authors:  Akiko Seki; Judith A Coppinger; Chang-Young Jang; John R Yates; Guowei Fang
Journal:  Science       Date:  2008-06-20       Impact factor: 47.728

Review 8.  From basic research to clinical development of MEK1/2 inhibitors for cancer therapy.

Authors:  Christophe Frémin; Sylvain Meloche
Journal:  J Hematol Oncol       Date:  2010-02-11       Impact factor: 17.388

9.  Loss of c-Met disrupts gene expression program required for G2/M progression during liver regeneration in mice.

Authors:  Valentina M Factor; Daekwan Seo; Tsuyoshi Ishikawa; Pal Kaposi-Novak; Jens U Marquardt; Jesper B Andersen; Elizabeth A Conner; Snorri S Thorgeirsson
Journal:  PLoS One       Date:  2010-09-16       Impact factor: 3.240

10.  Erk1/2 MAP kinases are required for epidermal G2/M progression.

Authors:  Phillip A Dumesic; Florence A Scholl; Deborah I Barragan; Paul A Khavari
Journal:  J Cell Biol       Date:  2009-05-04       Impact factor: 10.539

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.